LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
brief summary
The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarterial chemoembolization (TACE) or transarterial radioembolization (TARE).
detailed description
To evaluate the efficacy and safety of atezolizumab and bevacizumab compared to locoregional therapy (TACE or TARE) in patients with intermediate-stage HCC. The primary outcome is progression-free survival, which will be compared between two arms using stratified log-rank tests, adjusting the effect of stratification variables between two study arms. Cox regression analysis will be done to see if there are significant differences in PFS, controlling for the effects of confounding variables between the two study arms.
official title
Phase II Multi-center Randomized, Open-label, Trial of Atezolizumab and Bevacizumab vs Locoregional Therapy (Transarterial Chemoembozliation or Radioembolization) as First-line Therapy in Patients With Large Intermediate-stage Hepatocellular Carcinoma